Hiroshi Manya Selected Research

Walker-Warburg Syndrome

1/2016	Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan.
10/2013	GTDC2 modifies O-mannosylated α-dystroglycan in the endoplasmic reticulum to generate N-acetyl glucosamine epitopes reactive with CTD110.6 antibody.
8/2013	Novel POMGnT1 mutations cause muscle-eye-brain disease in Chinese patients.
8/2012	Functional and heterologous expression of human protein O-linked mannose β-1,2-N-acetylglucosaminyltransferase 1 in zebrafish.
7/2011	Effects of length and amino acid sequence of O-mannosyl peptides on substrate specificity of protein O-linked mannose β1,2-N-acetylglucosaminyltransferase 1 (POMGnT1).
1/2010	POMGnT1, POMT1, and POMT2 mutations in congenital muscular dystrophies.
1/2008	Protein O-mannosyltransferase activities in lymphoblasts from patients with alpha-dystroglycanopathies.
12/2006	Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.
7/2006	Physical and functional association of human protein O-mannosyltransferases 1 and 2.
1/2006	O-mannosylation in mammalian cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroshi Manya Research Topics

Disease

24	Muscular Dystrophies (Muscular Dystrophy) 01/2022 - 03/2002
16	Walker-Warburg Syndrome 01/2016 - 03/2002
5	Alzheimer Disease (Alzheimer's Disease) 11/2020 - 11/2008
2	Neoplasms (Cancer) 10/2021 - 08/2012
2	Eye Abnormalities (Eye Abnormality) 07/2006 - 10/2004
1	Cardiomyopathies (Cardiomyopathy) 01/2022
1	Amyloid Plaque 11/2020
1	Dementia (Dementias) 11/2020
1	Retinitis Pigmentosa (Pigmentary Retinopathy) 04/2016
1	Lissencephaly 03/2016
1	Melanoma (Melanoma, Malignant) 08/2012
1	Infections 11/2011
1	Chromosome Duplication 04/2011
1	Intellectual Disability (Idiocy) 04/2011
1	Neuroblastoma 01/2010
1	Neurodegenerative Diseases (Neurodegenerative Disease) 04/2004
1	Group II Malformations of Cortical Development 01/2004
1	Hydrocephalus (Hydrocephaly) 03/2003
1	Arteriosclerosis 09/2002
1	Protein Deficiency 09/2002

Drug/Important Bio-Agent (IBA)

16	Proteins (Proteins, Gene)FDA Link 11/2020 - 01/2004
14	Dystroglycans (Dystroglycan)IBA 01/2022 - 03/2002
12	Polysaccharides (Glycans)IBA 10/2021 - 11/2008
11	protein O-mannose beta-1,2-N-acetylglucosaminyltransferaseIBA 01/2020 - 03/2002
4	RibitolIBA 01/2022 - 03/2016
4	Amyloid (Amyloid Fibrils)IBA 11/2020 - 11/2008
3	Phosphates (Orthophosphate)IBA 01/2022 - 03/2016
3	Mannose (D-Mannose)IBA 01/2020 - 08/2012
2	EnzymesIBA 01/2022 - 01/2006
2	Laminin (Merosin)IBA 01/2018 - 04/2005
2	GlycosyltransferasesIBA 01/2016 - 12/2006
2	LigandsIBA 08/2012 - 03/2012
2	Amyloid beta-PeptidesIBA 01/2010 - 11/2008
2	protein O-mannosyltransferase (dolichyl-phosphate-mannose - protein mannosyltransferase)IBA 01/2008 - 01/2004
1	ProdrugsIBA 01/2022
1	cytidine diphosphate ribitolIBA 01/2022
1	Terpenes (Terpenoids)IBA 01/2022
1	TransferasesIBA 01/2020
1	Peptide Hydrolases (Proteases)FDA Link 02/2015
1	SugarsIBA 02/2015
1	Pharmaceutical PreparationsIBA 02/2015
1	Peptides (Polypeptides)IBA 02/2015
1	Alanine (L-Alanine)FDA Link 10/2013
1	O-GlcNAc transferaseIBA 10/2013
1	Epidermal Growth Factor (EGF)IBA 10/2013
1	SulfotransferasesIBA 08/2012
1	Sulfates (Sulfates, Inorganic)IBA 08/2012
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 08/2012
1	Galectin 1 (LGALS1)IBA 11/2011
1	DNA (Deoxyribonucleic Acid)IBA 04/2011
1	Messenger RNA (mRNA)IBA 01/2010
1	DystrophinIBA 01/2006
1	Glycoproteins (Glycoprotein)IBA 01/2006
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 04/2004
1	MannosyltransferasesIBA 01/2004
1	N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase (N-acetylglucosaminyltransferase)IBA 06/2003
1	mu-calpainIBA 09/2002
1	SpectrinIBA 09/2002

Therapy/Procedure

1	Therapeutics 01/2022